{
    "clinical_study": {
        "@rank": "19837", 
        "arm_group": [
            {
                "arm_group_label": "Salacia bark extract (SR-B-01) and TLC", 
                "arm_group_type": "Experimental", 
                "description": "Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)"
            }, 
            {
                "arm_group_label": "Sesame seeds extract (SI-S-01) and TLC", 
                "arm_group_type": "Experimental", 
                "description": "Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)"
            }, 
            {
                "arm_group_label": "Salacia leaf extract (SR-L-01) and TLC", 
                "arm_group_type": "Experimental", 
                "description": "Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)"
            }, 
            {
                "arm_group_label": "Placebo and TLC", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)"
            }
        ], 
        "brief_summary": {
            "textblock": "Objective of this study is to determine the safety and efficacy of administration of herbal\n      supplements (Salacia leaf extract, Salacia root extract and Sesame seed extract) for 6 weeks\n      in the management of prediabetes and mild to moderate hyperlipidemia."
        }, 
        "brief_title": "Safety and Efficacy Study of Herbal Supplements in Prediabetic and Mild to Moderate Hyperlipidemic Patients", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Prediabetes", 
            "Hyperlipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. As per ATP III guidelines: Baseline LDL ranging 160-189 mg/dL, TC >200 mg/dL and with\n             no or one of the below risk factors\n\n               -  Current cigarette smoking\n\n               -  Family history of premature Coronary Heart Disease(CHD); in male first  degree\n                  relative <55 years; in female first degree relative <65 years)\n\n               -  Hypertension (BP >140/90 mmHg or on antihypertensive medication)\n\n               -  Low HDL-C (<40 mg/dL)\n\n               -  Age (men > 40 years)\n\n          2. Impaired glucose tolerance (2-hour post 75 g OGTT glucose levels in the range of \u2265140\n             to \u2264 200 mg/dL)\n\n          3. Impaired fasting sugar (Fasting blood sugar levels in the range of \u2265 100 to \u2264125\n             mg/dL)\n\n          4. Being mentally competent and able to understand all study requirements and sign the\n             informed consent form.\n\n        Exclusion Criteria:\n\n          1. Patients with severe liver, renal, cardiac or brain diseases.\n\n          2. Pregnant or lactating women or women of child bearing potential whom are not\n             practicing a reliable form of birth control (either with IUD or with stable usage of\n             oral contraceptives).\n\n          3. Unable to complete follow up.\n\n          4. Subjects on any medication that would affect evaluation like Statins."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680211", 
            "org_study_id": "OL-S-OB-LP/03-12", 
            "secondary_id": "CTRI/2012/05/002678"
        }, 
        "intervention": [
            {
                "arm_group_label": "Salacia bark extract (SR-B-01) and TLC", 
                "intervention_name": "Salacia bark extract", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Salacia leaf extract (SR-L-01) and TLC", 
                "intervention_name": "Salacia leaf extract", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Sesame seeds extract (SI-S-01) and TLC", 
                "intervention_name": "Sesame seed extract", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Salacia bark extract (SR-B-01) and TLC", 
                    "Sesame seeds extract (SI-S-01) and TLC", 
                    "Salacia leaf extract (SR-L-01) and TLC", 
                    "Placebo and TLC"
                ], 
                "description": "Lifestyle changes include diet, exercise, weight loss, etc.", 
                "intervention_name": "TLC", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Placebo and TLC", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Blood Sugar,", 
            "Lipoproteins,", 
            "Salacia,", 
            "Sesame,", 
            "Prediabetes,", 
            "Hyperlipidemia,", 
            "Herbal supplement"
        ], 
        "lastchanged_date": "September 3, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangalore", 
                    "country": "India", 
                    "state": "Karnataka", 
                    "zip": "560050"
                }, 
                "name": "Srinivasa Clinic & Diabetic Care Center"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "4", 
        "official_title": "Efficacy and Safety Study of Herbal Supplements (SR-L-01, SR-B-01 and SI-S-01) in the Management of Prediabetes and Mild to Moderate Hyperlipidemia", 
        "overall_official": {
            "affiliation": "Srinivasa Clinic & Diabetic Care Center", 
            "last_name": "K R Raveendra, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in of blood sugar out come will be measured by Fasting Blood Sugar (FBS), Oral Glucose Tolerance Test (OGTT) and Postprandial Blood Sugar (PPBS). Change in lipid profiles are measured by Low Density Lipoprotein (LDL), Very Low Density Lipoprotein (VLDL), High Density Lipoprotein (HDL) and Total Cholesterol (TC).", 
            "measure": "Change in Blood Sugar and lipid profiles", 
            "safety_issue": "No", 
            "time_frame": "baseline and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680211"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Electrocardiography (ECG), haematology (Complete Blood Count), biochemical tests (blood urea, and serum creatinine), liver function tests and urine routine analysis", 
            "measure": "Clinical laboratory evaluations", 
            "safety_issue": "Yes", 
            "time_frame": "0 and week 6"
        }, 
        "source": "Olive Lifesciences Pvt Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Olive Lifesciences Pvt Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}